Lercanidipine Almus

Lercanidipine, the active ingredient in Lercanidipine Almus, is a calcium channel blocker presented as an oral tablet for oral use. It lowers elevated blood pressure in adult patients with hypertension.

GNH USA supplies Lercanidipine Almus as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is a dihydropyridine calcium channel blocker indicated for the management of hypertension and related blood‑pressure disorders. - Essential hypertension: lowers systolic and diastolic blood pressure. - Isolated systolic hypertension: provides vascular relaxation to reduce high systolic values. - Hypertension in elderly patients: offers once‑daily dosing with a favorable tolerability profile.

Lercanidipine may be associated with several adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Headache - Flushing - Peripheral edema - Dizziness

Serious or Rare Side Effects: - Severe hypotension - Angioedema - Myocardial infarction - Hepatic dysfunction

When prescribing Lercanidipine, clinicians should consider several safety aspects. - Blood pressure monitoring: measure BP before initiating therapy and periodically thereafter. - Renal impairment: use with caution in patients with severe renal dysfunction. - Hepatic impairment: dose adjustment may be required in moderate to severe liver disease. - Concomitant antihypertensives: avoid excessive hypotension when combined with other BP‑lowering agents. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Lercanidipine can interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels and risk of hypotension. - Grapefruit juice: can elevate drug concentration, leading to excessive blood‑pressure drop.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic efficacy. - Other antihypertensives (beta‑blockers, ACE inhibitors): may cause additive hypotensive effect. - Diuretics: may increase risk of electrolyte imbalance.